Fulgent Genetics Announces Promotion of Brandon Perthuis to Chief Commercial Officer
March 10 2020 - 8:00AM
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the
“company”), a provider of comprehensive genetic testing and Next
Generation Sequencing (“NGS”) solutions, today announced the
promotion of Brandon Perthuis to chief commercial officer (CCO).
Perthuis previously held the role of Vice President of Commercial
Operations with Fulgent since joining the company in May of 2017.
In his new role, Perthuis will continue to lead the company’s
global sales organization and commercialization effort as the
company focuses on both US and international expansion.
“We are very pleased to promote Brandon to this new
role,” said Ming Hsieh, Chairman and CEO of Fulgent Genetics.
“Brandon has been a major asset to our business and a key leader of
our sales organization since joining Fulgent in 2017. We look
forward to his ongoing contributions to our expanding
commercialization effort as we continue to scale. Brandon is a
driven leader with a deep understanding of our business and strong
relationships across the genetic testing industry. Under Brandon’s
sales leadership, our business has seen strong growth in both
billable test volume and revenue, while our customer base has
expanded nicely. Brandon has been a valuable contributor to our
growth over the last two and a half years, and we are excited for
him to expand his reach and relationships in this new role.”
Prior to joining Fulgent Genetics, Perthuis served
as Vice President of Sales and Marketing for Baylor Genetics in
Houston, Texas. Perthuis has over 16 years of experience in
clinical genetics and has built a network of deep relationships
across the genetic testing industry over this period. He will
report to Fulgent’s Chairman and CEO, Ming Hsieh.
About Fulgent Genetics
Fulgent Genetics is a growing technology company
with an initial focus on offering comprehensive genetic testing to
provide physicians with clinically actionable diagnostic
information they can use to improve the quality of patient care.
The company has developed a proprietary technology platform that
integrates sophisticated data comparison and suppression
algorithms, adaptive learning software, advanced genetic
diagnostics tools and integrated laboratory processes. This
platform allows the company to offer a broad and flexible test menu
and continually expand and improve its proprietary genetic
reference library, while maintaining accessible pricing, high
accuracy and competitive turnaround times. The company believes its
current test menu, which includes approximately 18,000 single-gene
tests and more than 850 pre-established, multi-gene,
disease-specific panels, offers more genes for testing than its
competitors in today’s market, which enables it to provide
expansive options for test customization and clinically actionable
results.
Investor Relations Contacts:The
Blueshirt GroupNicole Borsje,
415-217-2633, nborsje@blueshirtgroup.com
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Apr 2024 to May 2024
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From May 2023 to May 2024